Review anchor
Granulocyte colony-stimulating factor receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Granulocyte colony-stimulating factor receptor
CHEMBL1996
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Granulocyte colony-stimulating factor receptor as ChEMBL target CHEMBL1996, mapped to UniProt Q99062. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL1996
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q99062
Granulocyte colony-stimulating factor receptor
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Granulocyte colony-stimulating factor receptor matters
Granulocyte colony-stimulating factor receptor is reviewed as Granulocyte colony-stimulating factor receptor (UniProt Q99062); Granulocyte colony-stimulating factor receptor shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block.; 8 linked drugs keep this evidence frame grounded.; the current evidence base includes 0 approved drugs, 5 compounds, and 2 assays, with lead potency reaching pChEMBL 4.7.
Protein context
Granulocyte colony-stimulating factor receptor
Granulocyte colony-stimulating factor receptor Sequence length is 836 aa.
Review this target as Granulocyte colony-stimulating factor receptor, mapped to UniProt Q99062. Sequence length is 836 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q99062
Protein
Disease context
neoplasm
Granulocyte colony-stimulating factor receptor shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block. 8 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include BALUGRASTIM, EFBEMALENOGRASTIM ALFA, EFLAPEGRASTIM.
Start review with neoplasm because it currently carries approved-linked support. Linked drugs include BALUGRASTIM, EFBEMALENOGRASTIM ALFA, EFLAPEGRASTIM, FILGRASTIM. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
8 linked drugs
Activity base
Portfolio and assay base
ChEMBL currently tracks 0 approved drugs, 5 compounds, and 2 assays for this target. The dominant activity type is KD. CHEMBL602139 is the current potency anchor at pChEMBL 4.7.
Use CHEMBL602139 as the tractability anchor when discussing potency (pChEMBL 4.7).
Activity source · ChEMBL 36 via Core Engine
pChEMBL 4.7
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Granulocyte colony-stimulating factor receptor matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q99062, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why neoplasm is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
5
Total Compounds
2
Total Assays
0
Approved Drugs
KD: 4.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL602139
|
4.7 | Kd | — |
|
|
No preferred name
CHEMBL590814
|
4.3 | Kd | — |
Source Header